Loading…
Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study
Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC. The medical record...
Saved in:
| Published in: | Radiation oncology (London, England) England), 2022-02, Vol.17 (1), p.32-32, Article 32 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83 |
| container_end_page | 32 |
| container_issue | 1 |
| container_start_page | 32 |
| container_title | Radiation oncology (London, England) |
| container_volume | 17 |
| creator | Ogura, Yuta Terashima, Kazuki Nanno, Yoshihide Park, SungChul Suga, Masaki Takahashi, Daiki Matsuo, Yoshiro Sulaiman, Nor Shazrina Tokumaru, Sunao Okimoto, Tomoaki Toyama, Hirochika Fukumoto, Takumi |
| description | Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC.
The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes.
The median overall survival of the total cohort treated with GPT was 18.7 months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (P = 0.040 and P = 0.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1 months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60 Gy equivalents at gross tumor volume than those at the pancreatic head (P |
| doi_str_mv | 10.1186/s13014-022-02001-w |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fa1a8674db974a51a27abab8e0d1f4ed</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A693688202</galeid><doaj_id>oai_doaj_org_article_fa1a8674db974a51a27abab8e0d1f4ed</doaj_id><sourcerecordid>A693688202</sourcerecordid><originalsourceid>FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83</originalsourceid><addsrcrecordid>eNptkt9qFDEUxgdRbK2-gBcS8Mabqfk3MxkvhFKsFgreKHgXziRntikzyZpktuxz-YJmd2ttRUJIOPnO7-QkX1W9ZvSUMdW-T0xQJmvKeZmUsvr2SXXMOqnqjnU_nj7YH1UvUrqhVDaC9s-rI9EwKVvZHVe_LsDkEBOBlIJxkNGSW5evyRT8qs4YZ5KWuHEbmIjzZIWzcRkG57E2wZslRvSZrGPIwZMI1oV8jRHWWzKGSHzw9YwZUobsTGEamKYtAbsBb0qldVki7s_MLhI_ECDJ-dVU8AWMkUTMMaQ1muw2SFJe7PZl9WyEKeGru_Wk-n7x6dv5l_rq6-fL87Or2rQtz_WI_dCIgfVcADTIuUDFAVUnm1FaMSAzylIQhgIyOjaDsjjSzije9oCgxEl1eeDaADd6Hd0McasDOL0PhLjSEMvdJ9QjMFBtJ-3QdxIaBryDAQaF1LJRoi2sjwfWehlmtLvmIkyPoI9PvLvWq7DRSgneSVkA7-4AMfxcMGU9u2RwmsBjWJLmLVe8b5TY3fvtP9KbsERfnqqoBJWc8q79q1pBacD5MZS6ZgfVZ20vWqWKrqhO_6Mqw-LsigNwdCX-KIEfEkz5thRxvO-RUb2zrT7YVhfb6r1t9W1JevPwde5T_vhU_AZ-KO79</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630420276</pqid></control><display><type>article</type><title>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Ogura, Yuta ; Terashima, Kazuki ; Nanno, Yoshihide ; Park, SungChul ; Suga, Masaki ; Takahashi, Daiki ; Matsuo, Yoshiro ; Sulaiman, Nor Shazrina ; Tokumaru, Sunao ; Okimoto, Tomoaki ; Toyama, Hirochika ; Fukumoto, Takumi</creator><creatorcontrib>Ogura, Yuta ; Terashima, Kazuki ; Nanno, Yoshihide ; Park, SungChul ; Suga, Masaki ; Takahashi, Daiki ; Matsuo, Yoshiro ; Sulaiman, Nor Shazrina ; Tokumaru, Sunao ; Okimoto, Tomoaki ; Toyama, Hirochika ; Fukumoto, Takumi</creatorcontrib><description>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC.
The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes.
The median overall survival of the total cohort treated with GPT was 18.7 months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (P = 0.040 and P = 0.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1 months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60 Gy equivalents at gross tumor volume than those at the pancreatic head (P < 0.001). LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6 months after GTP than those without anterior peripancreatic invasion (P = 0.039).
GPT is a promising treatment option for patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.</description><identifier>ISSN: 1748-717X</identifier><identifier>EISSN: 1748-717X</identifier><identifier>DOI: 10.1186/s13014-022-02001-w</identifier><identifier>PMID: 35144647</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic ; Cancer ; Cancer therapies ; Care and treatment ; Chemoradiotherapy ; Chemotherapy ; Combined Modality Therapy ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Diagnosis ; Dosage and administration ; Female ; Gemcitabine ; Health care facilities ; Humans ; Ion beams ; Lymphatic system ; Male ; Medical prognosis ; Medical records ; Metastases ; Metastasis ; Methods ; Middle Aged ; Multivariate analysis ; Neoplasm Staging ; Pancreatic cancer ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; Patients ; Prognosis ; Prognostic factor ; Proton beam radiotherapy ; Proton radiotherapy ; Proton Therapy ; Protons ; Radiation therapy ; Radiation-Sensitizing Agents - therapeutic use ; Retrospective Studies ; Retrospective study ; Small intestine ; Spinal cord ; Survival ; Survival Rate ; Tails ; Time Factors ; Tomography ; Tumors ; Veins & arteries</subject><ispartof>Radiation oncology (London, England), 2022-02, Vol.17 (1), p.32-32, Article 32</ispartof><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83</citedby><cites>FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83</cites><orcidid>0000-0003-0360-8460</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832744/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2630420276?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,44569,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35144647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogura, Yuta</creatorcontrib><creatorcontrib>Terashima, Kazuki</creatorcontrib><creatorcontrib>Nanno, Yoshihide</creatorcontrib><creatorcontrib>Park, SungChul</creatorcontrib><creatorcontrib>Suga, Masaki</creatorcontrib><creatorcontrib>Takahashi, Daiki</creatorcontrib><creatorcontrib>Matsuo, Yoshiro</creatorcontrib><creatorcontrib>Sulaiman, Nor Shazrina</creatorcontrib><creatorcontrib>Tokumaru, Sunao</creatorcontrib><creatorcontrib>Okimoto, Tomoaki</creatorcontrib><creatorcontrib>Toyama, Hirochika</creatorcontrib><creatorcontrib>Fukumoto, Takumi</creatorcontrib><title>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study</title><title>Radiation oncology (London, England)</title><addtitle>Radiat Oncol</addtitle><description>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC.
The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes.
The median overall survival of the total cohort treated with GPT was 18.7 months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (P = 0.040 and P = 0.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1 months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60 Gy equivalents at gross tumor volume than those at the pancreatic head (P < 0.001). LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6 months after GTP than those without anterior peripancreatic invasion (P = 0.039).
GPT is a promising treatment option for patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Gemcitabine</subject><subject>Health care facilities</subject><subject>Humans</subject><subject>Ion beams</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prognostic factor</subject><subject>Proton beam radiotherapy</subject><subject>Proton radiotherapy</subject><subject>Proton Therapy</subject><subject>Protons</subject><subject>Radiation therapy</subject><subject>Radiation-Sensitizing Agents - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Retrospective study</subject><subject>Small intestine</subject><subject>Spinal cord</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tails</subject><subject>Time Factors</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Veins & arteries</subject><issn>1748-717X</issn><issn>1748-717X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt9qFDEUxgdRbK2-gBcS8Mabqfk3MxkvhFKsFgreKHgXziRntikzyZpktuxz-YJmd2ttRUJIOPnO7-QkX1W9ZvSUMdW-T0xQJmvKeZmUsvr2SXXMOqnqjnU_nj7YH1UvUrqhVDaC9s-rI9EwKVvZHVe_LsDkEBOBlIJxkNGSW5evyRT8qs4YZ5KWuHEbmIjzZIWzcRkG57E2wZslRvSZrGPIwZMI1oV8jRHWWzKGSHzw9YwZUobsTGEamKYtAbsBb0qldVki7s_MLhI_ECDJ-dVU8AWMkUTMMaQ1muw2SFJe7PZl9WyEKeGru_Wk-n7x6dv5l_rq6-fL87Or2rQtz_WI_dCIgfVcADTIuUDFAVUnm1FaMSAzylIQhgIyOjaDsjjSzije9oCgxEl1eeDaADd6Hd0McasDOL0PhLjSEMvdJ9QjMFBtJ-3QdxIaBryDAQaF1LJRoi2sjwfWehlmtLvmIkyPoI9PvLvWq7DRSgneSVkA7-4AMfxcMGU9u2RwmsBjWJLmLVe8b5TY3fvtP9KbsERfnqqoBJWc8q79q1pBacD5MZS6ZgfVZ20vWqWKrqhO_6Mqw-LsigNwdCX-KIEfEkz5thRxvO-RUb2zrT7YVhfb6r1t9W1JevPwde5T_vhU_AZ-KO79</recordid><startdate>20220210</startdate><enddate>20220210</enddate><creator>Ogura, Yuta</creator><creator>Terashima, Kazuki</creator><creator>Nanno, Yoshihide</creator><creator>Park, SungChul</creator><creator>Suga, Masaki</creator><creator>Takahashi, Daiki</creator><creator>Matsuo, Yoshiro</creator><creator>Sulaiman, Nor Shazrina</creator><creator>Tokumaru, Sunao</creator><creator>Okimoto, Tomoaki</creator><creator>Toyama, Hirochika</creator><creator>Fukumoto, Takumi</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0360-8460</orcidid></search><sort><creationdate>20220210</creationdate><title>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study</title><author>Ogura, Yuta ; Terashima, Kazuki ; Nanno, Yoshihide ; Park, SungChul ; Suga, Masaki ; Takahashi, Daiki ; Matsuo, Yoshiro ; Sulaiman, Nor Shazrina ; Tokumaru, Sunao ; Okimoto, Tomoaki ; Toyama, Hirochika ; Fukumoto, Takumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Gemcitabine</topic><topic>Health care facilities</topic><topic>Humans</topic><topic>Ion beams</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prognostic factor</topic><topic>Proton beam radiotherapy</topic><topic>Proton radiotherapy</topic><topic>Proton Therapy</topic><topic>Protons</topic><topic>Radiation therapy</topic><topic>Radiation-Sensitizing Agents - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Retrospective study</topic><topic>Small intestine</topic><topic>Spinal cord</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tails</topic><topic>Time Factors</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogura, Yuta</creatorcontrib><creatorcontrib>Terashima, Kazuki</creatorcontrib><creatorcontrib>Nanno, Yoshihide</creatorcontrib><creatorcontrib>Park, SungChul</creatorcontrib><creatorcontrib>Suga, Masaki</creatorcontrib><creatorcontrib>Takahashi, Daiki</creatorcontrib><creatorcontrib>Matsuo, Yoshiro</creatorcontrib><creatorcontrib>Sulaiman, Nor Shazrina</creatorcontrib><creatorcontrib>Tokumaru, Sunao</creatorcontrib><creatorcontrib>Okimoto, Tomoaki</creatorcontrib><creatorcontrib>Toyama, Hirochika</creatorcontrib><creatorcontrib>Fukumoto, Takumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Radiation oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogura, Yuta</au><au>Terashima, Kazuki</au><au>Nanno, Yoshihide</au><au>Park, SungChul</au><au>Suga, Masaki</au><au>Takahashi, Daiki</au><au>Matsuo, Yoshiro</au><au>Sulaiman, Nor Shazrina</au><au>Tokumaru, Sunao</au><au>Okimoto, Tomoaki</au><au>Toyama, Hirochika</au><au>Fukumoto, Takumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study</atitle><jtitle>Radiation oncology (London, England)</jtitle><addtitle>Radiat Oncol</addtitle><date>2022-02-10</date><risdate>2022</risdate><volume>17</volume><issue>1</issue><spage>32</spage><epage>32</epage><pages>32-32</pages><artnum>32</artnum><issn>1748-717X</issn><eissn>1748-717X</eissn><abstract>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC.
The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes.
The median overall survival of the total cohort treated with GPT was 18.7 months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (P = 0.040 and P = 0.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1 months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60 Gy equivalents at gross tumor volume than those at the pancreatic head (P < 0.001). LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6 months after GTP than those without anterior peripancreatic invasion (P = 0.039).
GPT is a promising treatment option for patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>35144647</pmid><doi>10.1186/s13014-022-02001-w</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0360-8460</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1748-717X |
| ispartof | Radiation oncology (London, England), 2022-02, Vol.17 (1), p.32-32, Article 32 |
| issn | 1748-717X 1748-717X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_fa1a8674db974a51a27abab8e0d1f4ed |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic Cancer Cancer therapies Care and treatment Chemoradiotherapy Chemotherapy Combined Modality Therapy Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Diagnosis Dosage and administration Female Gemcitabine Health care facilities Humans Ion beams Lymphatic system Male Medical prognosis Medical records Metastases Metastasis Methods Middle Aged Multivariate analysis Neoplasm Staging Pancreatic cancer Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Patients Prognosis Prognostic factor Proton beam radiotherapy Proton radiotherapy Proton Therapy Protons Radiation therapy Radiation-Sensitizing Agents - therapeutic use Retrospective Studies Retrospective study Small intestine Spinal cord Survival Survival Rate Tails Time Factors Tomography Tumors Veins & arteries |
| title | Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T17%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20associated%20with%20long-term%20survival%20in%20gemcitabine-concurrent%20proton%20radiotherapy%20for%20non-metastatic%20locally%20advanced%20pancreatic%20cancer:%20a%20single-center%20retrospective%20study&rft.jtitle=Radiation%20oncology%20(London,%20England)&rft.au=Ogura,%20Yuta&rft.date=2022-02-10&rft.volume=17&rft.issue=1&rft.spage=32&rft.epage=32&rft.pages=32-32&rft.artnum=32&rft.issn=1748-717X&rft.eissn=1748-717X&rft_id=info:doi/10.1186/s13014-022-02001-w&rft_dat=%3Cgale_doaj_%3EA693688202%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c662t-fe9b53b1923aa5e223e82ae8745f4d3be1c8d0a3c0ae10f5b8def07c8269aea83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2630420276&rft_id=info:pmid/35144647&rft_galeid=A693688202&rfr_iscdi=true |